[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-1-en-105":3,"doc-seo-563209-105":53,"doc-detail-563209-en":127},{"code":4,"msg":5,"data":6},0,"success",[7,14,19,24,29,34,39,44,49],{"id":8,"doc_module":9,"doc_module_name":10,"category_name":11,"show_sort_weight":12,"slug":13},11,1,"Template","Presentations",90,"presentations",{"id":15,"doc_module":9,"doc_module_name":10,"category_name":16,"show_sort_weight":17,"slug":18},12,"Resumes",80,"resumes",{"id":20,"doc_module":9,"doc_module_name":10,"category_name":21,"show_sort_weight":22,"slug":23},14,"Invoices",70,"invoices",{"id":25,"doc_module":9,"doc_module_name":10,"category_name":26,"show_sort_weight":27,"slug":28},15,"Posters",60,"posters",{"id":30,"doc_module":9,"doc_module_name":10,"category_name":31,"show_sort_weight":32,"slug":33},16,"Social Media",50,"social-media",{"id":35,"doc_module":9,"doc_module_name":10,"category_name":36,"show_sort_weight":37,"slug":38},17,"Forms",40,"forms",{"id":40,"doc_module":9,"doc_module_name":10,"category_name":41,"show_sort_weight":42,"slug":43},18,"Letters",30,"letters",{"id":45,"doc_module":9,"doc_module_name":10,"category_name":46,"show_sort_weight":47,"slug":48},21,"Paper Templates",5,"papers-templates",{"id":50,"doc_module":9,"doc_module_name":10,"category_name":51,"show_sort_weight":4,"slug":52},158,"General","general-158",{"code":4,"msg":54,"data":55},"ok",{"site_id":56,"language":57,"slug":58,"title":59,"keywords":60,"description":61,"schema_data":62,"social_meta":120,"head_meta":122,"extra_data":124,"updated_unix":126},105,"en","wegovy-product-information-annex-i-summary-of-product-characteristics","Wegovy Product Information - Annex I - Summary of Product Characteristics","","Annex I presents the Summary of Product Characteristics for Wegovy, a semaglutide-based solution for injection in pre-filled pen or pre-filled syringe. It covers additional safety monitoring, reporting of suspected adverse reactions, and lists multiple strengths and presentations. The document provides qualitative and quantitative composition details, including semaglutide content per mL and notes on the human GLP-1 analogue. It also describes the pharmaceutical form and key clinical indications for adults and adolescents.",{"@graph":63,"@context":119},[64,80,102],{"@type":65,"itemListElement":66},"BreadcrumbList",[67,71,74,77],{"item":68,"name":69,"@type":70,"position":9},"https://docshare.wps.com","Home","ListItem",{"item":72,"name":10,"@type":70,"position":73},"https://docshare.wps.com/template/",2,{"item":75,"name":51,"@type":70,"position":76},"https://docshare.wps.com/template/general/",3,{"item":78,"name":59,"@type":70,"position":79},"https://docshare.wps.com/template/wegovy-product-information-annex-i-summary-of-product-characteristics/563209/",4,{"url":78,"name":59,"@type":81,"image":82,"author":87,"headline":59,"publisher":90,"fileFormat":93,"inLanguage":57,"description":61,"dateModified":94,"datePublished":95,"encodingFormat":93,"isAccessibleForFree":96,"interactionStatistic":97},"DigitalDocument",{"url":83,"@type":84,"width":85,"height":86},"https://docshare.wps.com/thumbnails/wegovy-product-information-annex-i-summary-of-product-characteristics/563209.png","ImageObject",442,249,{"name":88,"@type":89},"Blitz","Person",{"url":68,"name":91,"@type":92},"DocShare","Organization","application/pdf","2026-10-30","2026-10-12",true,{"@type":98,"interactionType":99,"userInteractionCount":101},"InteractionCounter",{"@type":100},"ViewAction",8,{"@type":103,"mainEntity":104},"FAQPage",[105,111,115],{"name":106,"@type":107,"acceptedAnswer":108},"What is the purpose of Annex I in this document?","Question",{"text":109,"@type":110},"Annex I provides the Summary of Product Characteristics, including key information about Wegovy’s composition, pharmaceutical form, and therapeutic indications, along with safety monitoring and adverse reaction reporting instructions.","Answer",{"name":112,"@type":107,"acceptedAnswer":113},"What drug products and strengths are listed for Wegovy?",{"text":114,"@type":110},"Wegovy is listed in multiple strengths for injection, including pre-filled pen (e.g., 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg, and 7.2 mg) and pre-filled syringe, with corresponding semaglutide amounts per mL.",{"name":116,"@type":107,"acceptedAnswer":117},"For whom is Wegovy indicated according to the therapeutic indications section?",{"text":118,"@type":110},"For adults, it is indicated for weight management as an adjunct to reduced-calorie diet and increased physical activity for specified BMI ranges and comorbidity conditions. For adolescents, it is indicated as an adjunct for weight management in those aged at least 12 years.","https://schema.org",{"og:url":78,"og:type":121,"og:title":59,"og:site_name":91,"og:description":61},"article",{"robots":123,"canonical":78},"index,follow",{"doc_id":125,"site_id":56},563209,1792087002,{"code":4,"msg":5,"data":128},{"doc_id":125,"user_id":129,"nickname":88,"user_avatar":130,"doc_module":9,"category_id":50,"category_name":51,"doc_title":59,"doc_description":61,"doc_content":131,"file_id":132,"file_url":133,"file_type":134,"file_size":135,"view_count":101,"is_deleted":4,"is_public":9,"is_downloadable":9,"audit_status":9,"page_count":136,"language":137,"language_code":57,"site_id":56,"html_lang":57,"table_of_contents":138,"faqs":139,"seo_title":140,"seo_description":61,"update_tm":141,"read_time":142},24464137899374,"https://us-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","ANNEX I  \nSUMMARY OF PRODUCT CHARACTERISTICS  \nThis medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how to report adverse reactions.  \n1. NAME OF THE MEDICINAL PRODUCT  \nWegovy 0.25 mg solution for injection in pre-filled pen  \nWegovy 0.5 mg solution for injection in pre-filled pen  \nWegovy 1 mg solution for injection in pre-filled pen  \nWegovy 1.7 mg solution for injection in pre-filled pen  \nWegovy 2.4 mg solution for injection in pre-filled pen  \nWegovy 7.2 mg solution for injection in pre-filled pen  \nWegovy 0.25 mg FlexTouch solution for injection in pre-filled pen  \nWegovy 0.5 mg FlexTouch solution for injection in pre-filled pen  \nWegovy 1 mg FlexTouch solution for injection in pre-filled pen  \nWegovy 1.7 mg FlexTouch solution for injection in pre-filled pen  \nWegovy 2.4 mg FlexTouch solution for injection in pre-filled pen Wegovy 0.25 mg solution for injection in pre-filled syringe  \nWegovy 0.5 mg solution for injection in pre-filled syringe  \nWegovy 1 mg solution for injection in pre-filled syringe  \nWegovy 1.7 mg solution for injection in pre-filled syringe  \nWegovy 2.4 mg solution for injection in pre-filled syringe  \n2. QUALITATIVE AND QUANTITATIVE COMPOSITION  \nPre-filled pen, single-dose  \nWegovy 0.25 mg solution for injection in pre-filled pen  \nEach single-dose pre-filled pen contains 0.25 mg semaglutide* in 0.5 mL solution. One mL of solution contains 0.5 mg semaglutide * .  \nWegovy 0.5 mg solution for injection in pre-filled pen  \nEach single-dose pre-filled pen contains 0.5 mg semaglutide* in 0.5 mL solution. One mL of solution contains 1 mg semaglutide* .  \nWegovy 1 mg solution for injection in pre-filled pen  \nEach single-dose pre-filled pen contains 1 mg semaglutide* in 0.5 mL solution. One mL of solution contains 2 mg semaglutide* .  \nWegovy 1.7 mg solution for injection in pre-filled pen  \nEach single-dose pre-filled pen contains 1.7 mg semaglutide* in 0.75 mL solution. One mL of solution contains 2.27 mg semaglutide * .  \nWegovy 2.4 mg solution for injection in pre-filled pen  \nEach single-dose pre-filled pen contains 2.4 mg semaglutide* in 0.75 mL solution. One mL of solution contains 3.2 mg semaglutide * .  \nWegovy 7.2 mg solution for injection in pre-filled pen  \nEach single-dose pre-filled pen contains 7.2 mg semaglutide* in 0.75 mL solution. One mL of solution contains 9.6 mg semaglutide* .  \nPre-filled pen, FlexTouch  \nWegovy 0.25 mg FlexTouch solution for injection in pre-filled pen  \nEach pre-filled pen contains 1 mg semaglutide * in 1.5 mL solution. One mL of solution contains 0.68 mg semaglutide* . One pre-filled pen contains 4 doses of 0.25 mg.  \nWegovy 0.5 mg FlexTouch solution for injection in pre-filled pen  \n1.5 mL: Each pre-filled pen contains 2 mg semaglutide* in 1.5 mL solution. One mL of solution contains 1.34 mg semaglutide* . One pre-filled pen contains 4 doses of 0.5 mg.  \n3 mL: Each pre-filled pen contains 2 mg semaglutide* in 3 mL solution. One mL of solution contains 0.68 mg semaglutide* . One pre-filled pen contains 4 doses of 0.5 mg.  \nWegovy 1 mg FlexTouch solution for injection in pre-filled pen  \nEach pre-filled pen contains 4 mg semaglutide * in 3 mL solution. One mL of solution contains  \n1.34 mg semaglutide* . One pre-filled pen contains 4 doses of 1 mg.  \nWegovy 1.7 mg FlexTouch solution for injection in pre-filled pen  \nEach pre-filled pen contains 6.8 mg semaglutide * in 3 mL solution. One mL of solution contains  \n2.27 mg semaglutide* . One pre-filled pen contains 4 doses of 1.7 mg.  \nWegovy 2.4 mg FlexTouch solution for injection in pre-filled pen  \nEach pre-filled pen contains 9.6 mg semaglutide * in 3 mL solution. One mL of solution contains  \n3.2 mg semaglutide* . One pre-filled pen contains 4 doses of 2.4 mg.  \nPre-filled syringe  \nWegovy 0.25 mg solution for injection in pre-filled syringe  \nEa","cbCaianZ3ZvifpzP","https://ap.wps.com/l/cbCaianZ3ZvifpzP","pdf",1588176,182,"English","# Annex I\n## Summary of Product Characteristics\n## Name of the medicinal product\n## Qualitative and quantitative composition\n## Pharmaceutical form\n## Clinical particulars\n### Therapeutic indications","[{\"question\":\"What is the purpose of Annex I in this document?\",\"answer\":\"Annex I provides the Summary of Product Characteristics, including key information about Wegovy’s composition, pharmaceutical form, and therapeutic indications, along with safety monitoring and adverse reaction reporting instructions.\"},{\"question\":\"What drug products and strengths are listed for Wegovy?\",\"answer\":\"Wegovy is listed in multiple strengths for injection, including pre-filled pen (e.g., 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg, and 7.2 mg) and pre-filled syringe, with corresponding semaglutide amounts per mL.\"},{\"question\":\"For whom is Wegovy indicated according to the therapeutic indications section?\",\"answer\":\"For adults, it is indicated for weight management as an adjunct to reduced-calorie diet and increased physical activity for specified BMI ranges and comorbidity conditions. For adolescents, it is indicated as an adjunct for weight management in those aged at least 12 years.\"}]","Wegovy Product Information - Annex I - Summary of Product Characteristics | PDF",1791821686,64]